Jiangsu HengRui Medicine Co., Ltd.: clinical-trial pipeline
Jiangsu HengRui Medicine Co., Ltd. is the sponsor of 570 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 91 are not yet finished and 3 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 1 | 278 |
| Phase 3 | 124 |
| Phase 2 | 112 |
| Phase 1/2 | 39 |
| Phase 2/3 | 9 |
| Phase 4 | 5 |
| Not applicable | 3 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 283 |
| Unknown | 158 |
| Recruiting | 53 |
| Terminated | 29 |
| Active, not recruiting | 25 |
| Not yet recruiting | 13 |
| Withdrawn or not authorised | 6 |
| Suspended or halted | 3 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 262 |
| Metabolic and endocrine (diabetes, obesity) | 63 |
| Gastroenterology and liver | 47 |
| Nephrology and urology | 43 |
| Immunology and rheumatology | 30 |
| Cardiovascular | 29 |
| Haematology | 26 |
| Women's health and obstetrics | 20 |
| Dermatology | 11 |
| Infectious disease and vaccines | 11 |
| Musculoskeletal | 8 |
| Respiratory | 8 |
Countries
| Country | Trials |
|---|---|
| China | 511 |
| United States | 10 |
| Australia | 8 |
| South Korea | 6 |
| Poland | 5 |
| Spain | 4 |
| Taiwan | 4 |
| Belgium | 3 |
| France | 3 |
| Italy | 3 |
| Russia | 3 |
| Bulgaria | 2 |
| Czechia | 2 |
| Germany | 2 |
| Moldova | 2 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-09-08 | New trial posted | An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With An… |
| 2026-09-01 | New trial posted | A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and… |
| 2026-08-27 | New trial posted | FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Re… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abir… | Phase 3 | Active, not recruiting | Australia, Belgium, China, Czechia +9 |
| NCT03520478 | A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer | Phase 3 | Not yet recruiting | Bulgaria, China, Czechia, Poland |
| NCT07286032 | A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemot… | Phase 3 | Recruiting | Bulgaria, China, Spain, France +6 |
| NCT07070349 | A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors | Phase 1/2 | Recruiting | China |
| NCT06126640 | A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Prima… | Phase 3 | Active, not recruiting | China |
| NCT05945901 | A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevaci… | Phase 2/3 | Active, not recruiting | China |
| NCT06529432 | A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery | Phase 2 | Recruiting | China |
| NCT07175220 | Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung C… | Phase 2 | Recruiting | China |
| NCT07232849 | A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic N… | Phase 2 | Recruiting | China |
| NCT06598735 | A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy… | Phase 1 | Recruiting | China |
| NCT06385678 | A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation | Phase 1/2 | Active, not recruiting | China |
| NCT06099990 | Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) V… | Phase 1 | Not yet recruiting | |
| NCT07796763 | A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First… | Phase 2 | Not yet recruiting | United States |
| NCT06413745 | Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unr… | Phase 2 | Active, not recruiting | China |
| NCT07032688 | A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects W… | Phase 1 | Recruiting | China |
| NCT06568094 | A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | Phase 1/2 | Recruiting | China |
| NCT07489482 | A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection | Phase 1 | Recruiting | China |
| NCT07362355 | The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary… | Phase 2 | Recruiting | China |
| NCT07232875 | HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metasta… | Phase 3 | Recruiting | China |
| NCT05424835 | A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or M… | Phase 3 | Active, not recruiting | China |
| NCT07746726 | Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults | Phase 3 | Recruiting | China |
| NCT06344091 | A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients | Phase 4 | Recruiting | China |
| NCT05482568 | A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small… | Phase 1/2 | Recruiting | China |
| NCT04842617 | Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Recept… | Phase 3 | Active, not recruiting | China |
| NCT07003321 | A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | Recruiting | China |
Website: hengrui.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Jiangsu HengRui Medicine Co., Ltd. clinical trials: 91 open, 133 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/hengrui-com/, data as of 2026-10-25.